-
TCR-T therapy ORR up to 80%! In the field of solid tumors, CAR-T/NK and TIL each show their powers
Time of Update: 2022-10-20
October 12, 2022 / eMedClub News / -- On October 10, Immatics announced the results of its latest clinical trial of IMA203, a TCR-T therapy targeting the PRAME antigen 。 Overall, IMA203 is well tolera
-
Summary of common anti-tumor drug dosage and adverse reaction treatment!
Time of Update: 2022-10-20
Find "tumor" in the channelAnd pay attentionDownload the Doctor Station App and subscribe anytime, anywhere~*For medical professionals onlyCommon antitumor drug usage and dosage, adverse reactions.
Find "tumor" in the channelAnd pay attentionDownload the Doctor Station App and subscribe anytime, anywhere~*For medical professionals onlyCommon antitumor drug usage and dosage, adverse reactions.
-
Professor Hu Jie: There are many abnormal manifestations of MET pathway, and the treatment of sevotinib is widely used, and clinical cases provide new treatment ideas
Time of Update: 2022-10-20
*For medical professionals onlyThe essence of MET excellent cases in September~The launch of highly selective MET-TKI sevotinib undoubtedly opens up a new path for targeted therapy for lung cancer. In
-
CA: Breast cancer mortality has dropped by 43% in 30 years, what are the differences between China and the United States?
Time of Update: 2022-10-20
1Morbidity and mortality "drifting away"Breast cancer rates in the United States have been on the rise for most of the past 40 years: in the '80s and '90s, largely due to increased detection rates of asymptomatic disease during the rapid adoption of mammography screening.
-
【PNAS】Northwestern University research found that lipid balance - a key factor regulating cancer cell metastasis and survival
Time of Update: 2022-10-20
This article is the original of Translational Medicine Network, please indicate the source of reprinting Written by SophiaFatty acids are an important source of energy and a key component of phospholi
-
The sense of smell regulates glioma formation through olfactory nerve functional circuits
Time of Update: 2022-10-20
Academician Duan Shumin of the Department of Neurosurgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, used previously constructed mouse models of endophytic glioma to confirm that the sense of smell can directly regulate the formation of glioma.
-
Express For the treatment of chronic lymphocytic leukemia, BeiGene BTK inhibitor phase 3 clinical results are positive
Time of Update: 2022-10-20
▲If you have any business needs, please long press to scan the QR code above, or▎WuXi AppTec content team editorToday, BeiGene announced that its Bruton's tyrosine kinase (BTK) small molecule inhibitor, BRUKINSA (zebrutinib), has achieved positive results in a global Phase 3 clinical trial called ALPINE, where zebrutinib has achieved progression-free survival (PFS) results in the treatment of chronic lymphocytic leukemia (CLL) compared with active control BTK inhibitors by an independent review committee (IRC) and investigators.
-
Mi Qi Xing Xie Feng Jifeng and Professor Qiu Lugui: Turn the tide, and Pola will guide the repeated progress of DLBCL
Time of Update: 2022-10-20
GuideEvery unknown world is opened with pioneers who bravely foresee; Every journey of sneaking through the dark night is fearlessly led by the lighter. The series of reports "Solving the Problem - Un
-
Celebrity Club Based on practice, building dreams of the future, the treatment of triple positive breast cancer
Time of Update: 2022-10-20
Triple-positive breast cancer (TPBC) is a special type of breast cancer expressed by hormone receptor (HR) positive (HR+) and human epidermal growth factor receptor (HER2) positive (HER2+), with uniqu
-
【PNAS】The research group of Ma Xianjue/Li Xu of Westlake University revealed a new mechanism of UPR regulation of Hippo signaling pathway mediated tumor progression
Time of Update: 2022-10-20
On October 10, 2022, Ma Xianjue's research group at the School of Life Sciences, Westlake University and Li Xu's research group jointly published a research paper elaborating the molecular mechanism of the Ire1/Xbp1s branch of UPR regulating organ size, intestinal stem cell homeostasis, cell migration and tumorigenesis and development through the Hippo pathway.
-
Change cognition! NEJM over 80,000 people study: colorectal cancer screening "gold standard", role or overestimated?
Time of Update: 2022-10-20
The results of a pooled analysis study (including 3 randomized clinical trials) showed that the incidence of colorectal cancer was reduced by as much as 25% after 10~12 years of follow-up of subjects who underwent sigmoidoscopy screening.
-
【PNAS】Tsinghua Chen Mo Research Group: Composition mechanism of key transcription complexes of leukemia and new therapeutic targets
Time of Update: 2022-10-20
This study demonstrates that the AETFC complex recruits CARM1 to chromatin, thereby activating target gene expression and promoting AML cell survival, describing the novel role of the cancer transcription factor LYL1 in AETFC assembly and gene activation.
-
Terrible paraneoplastic complications, does targeted therapy work?
Time of Update: 2022-10-20
Malignant tumors such as lung cancer can have some serious paraneoplastic complications, resulting in a very poor prognosis and affecting normal treatment, such as disseminated intravascular coagulation (DIC), which is a complication characterized by thrombosis, bleeding, and thrombocytopenia, and if not treated in time, the patient's life will be in danger.
-
This article reviews the progress of targeted therapy for breast cancer with low | expression of HER2
Time of Update: 2022-10-20
However, subsequent NSABP B-47 studies (phase III) [6], with the addition of trastuzumab to standard adjuvant therapy, failed to demonstrate a survival benefit for low-HER2-expressing BCs (regardless of IHC 1+/2+) (Table 1).
-
Express Targeting Undruggable Cancer Targets! A Bayer subsidiary supports the development of precision medicines with USD 930 million
Time of Update: 2022-10-20
▎WuXi AppTec content team editorVividion Therapeutics, a Bayer unit, and Tavros Therapeutics jointly announced a strategic collaboration agreement to jointly discover or target four oncology targets over the first 5 years.
-
"Pacific" PACIFIC-6 study in series: maintenance therapy with devalumab after sequential chemoradiotherapy
Time of Update: 2022-10-20
Background:Based on the phase III PACIFIC study, for patients with inoperable stage III non-small cell lung cancer, the disease has not progressed after receiving concurrent chemoradiotherapy, and 12 months of maintenance therapy with duvalumab is the current standard of care.
-
Express significantly prolongs overall survival for patients with metastatic breast cancer! Gilead ADC is eligible for priority review by the U.S. FDA
Time of Update: 2022-10-20
S. FDA has accepted a Supplemental Biologics License Application (sBLA) for its antibody-conjugate drug Trodelvy (sacituzumab govitecan) for the treatment of patients with HR-positive/HER2-negative metastatic breast cancer who have received multiple upfront treatments.
-
The latest data: China's liver cancer cases account for 45.3% of the world! How to prevent liver cancer?
Time of Update: 2022-10-20
Electronic Journal of Comprehensive Oncology, 2022, 8(3): 31-63 Guide Q&A mini-sessionFrom now on, the clinical guideline APP will launch a guide Q&A activity every Tuesday, Thursday and Saturday!Participate in the Q&A activity to have a chance to get rewards~The event entrances are as follows:Secondary preventiontargets people with chronic liver disease, controlling related causes and risk factors and screening and monitoring according to risk stratification to reduce or delay the occurrence of liver cancer.
-
Professor Qin Shukui: Pembrolizumab has been approved as a second-line treatment for advanced liver cancer, providing a new preferred drug for liver cancer patients in China
Time of Update: 2022-10-20
China is a country with a high incidence of primary liver cancer, with about 410,000 new liver cancer patients and about 390,000 deaths in 2020, the main type of which is hepatocellular carcinoma (HCC
-
Research Frontiers What are the differences in the benefits of targeted therapy in elderly mRCC patients?
Time of Update: 2022-10-20
Fig. 3 Analysis of risk factors for deathconclusionAll age groups showed improvement in OS during the targeted therapy period, and older patients could also benefit from targeted therapies such as TKIs. Suitable older patients can also benefit from participating after being evaluated.
